hotspot -WSS

hotspot

author：knowledge 2025-10-03 00:40:46 - browse：9

Adam's take main illustration — Molly Ferguson/STAT

This week, a preview of the TUDCA study in ALS and thoughts on how it might impact Amylyx Pharmaceuticals. Also, I chatted with CRISPR Therapeutics CEO Sam Kulkarni about its new investor. Read to the end for some burning questions, random thoughts.

The next ALS data readout — overdue but important

A European academic consortium is expected to announce results soon from a clinical trial investigating the use of a widely available nutritional supplement called tauroursodeoxycholic acid, or TUDCA, in people living with ALS. The outcome of the TUDCA-ALS study could have implications for Amylyx Pharmaceuticals, because TUDCA is one of the two main ingredients in Relyvrio, the company’s approved drug for ALS.

In a recent interview at Amylyx’s Kendall Square headquarters, co-CEOs Justin Klee and Josh Cohen mostly downplayed the suggestion that results from the randomized, placebo-controlled TUDCA study might affect Relyvrio negatively, or even positively.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Hearing on Medicare drug price negotiation gets unusually heated

knowledge

WSS

David Ricks of Eli Lilly: best biopharma CEO of 2023

David Ricks of Eli Lilly: best biopharma CEO of 2023

SNAP should offer more nutrition education

It's been 20 years since Dolly the sheep. Where's my clone?

Hospitals owned by private equity see complications spike 25%

FDA panel to weigh approval of NurOwn, controversial ALS drug

knowledge

hotspot

The next ALS data readout — overdue but important

hotspot

DIEP, the 'gold standard' of breast reconstruction, is under threat

CommonSpirit Health keeps growing, even as it loses money

Drug repurposing or repositioning? The language matters

HCA sued by state AG for quality issues at Mission Health

Alkermes shareholders re

Hearing on Medicare drug price negotiation gets unusually heated

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Lasker Awards 2023: Winners in biomedical research

Novavax promises a turnaround & Lilly roils the obesity market

Medicare Advantage beneficiaries sue Humana over algorithm use

knowledge

Senate HELP committee spars over health care workforce policies

Biotech lab space demand falls sharply

Drug for rare kidney disease narrowly misses mark in clinical trial

Why are Kaiser Permanente staff considering a strike?

Prime Medicine, Myeloid Therapeutics clash over genome

Changes to biosimilar regulatory framework must prioritize patients

knowledge

focus

entertainment

hotspot